We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    OPH1006
Previous Study | Return to List | Next Study

An 18 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02387957
First Posted: March 13, 2015
Last Update Posted: April 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ophthotech Corporation
  Purpose
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.

Condition Intervention Phase
Age-Related Macular Degeneration Drug: Fovista® Drug: bevacizumab Drug: ranibizumab Drug: aflibercept Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Ophthotech Corporation:

Primary Outcome Measures:
  • To evaluate the safety of Fovista (anti-PDGF BB) when administered in combination with anti-VEGF therapy as assessed by the incidence of test article related adverse events [ Time Frame: 18 Months ]

Enrollment: 64
Study Start Date: February 2015
Study Completion Date: March 2017
Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fovista® plus bevacizumab
Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
Drug: Fovista® Drug: bevacizumab
Other Name: Avastin®
Experimental: Fovista® plus ranibizumab
Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
Drug: Fovista® Drug: ranibizumab
Other Name: Lucentis®
Experimental: Fovista® plus aflibercept
Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
Drug: Fovista® Drug: aflibercept
Other Name: Eylea®

Detailed Description:

60 subjects randomized 1:1:1 and treated with IVT Fovista® 1.5 mg/eye in combination with anti-VEGF therapy as follows:

  • Avastin® 1.25 mg/eye (20 subjects)
  • Lucentis® 0.5 mg/eye (20 subjects)
  • Eylea® 2.0 mg/eye (20 subjects)

Subjects will be stratified by lesion size (≤2 DA vs. >2 DA).

Subjects will be treated with "combination therapy" of IVT Fovista® and IVT anti-VEGF therapy every month for the first 5 months (Day 1, Months 1,2,3,4), followed by Q12W (every 12 weeks) administration (Months 7,10, 13, and 16), for a total of 18 months.

When administered, IVT Fovista® will be given first, followed by IVT anti-VEGF (same day).

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects of either gender aged ≥ 50 years.
  • Active subfoveal choroidal neovascularization (CNV) due to AMD.

Exclusion Criteria:

  • Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication.
  • Subjects with subfoveal scar or subfoveal atrophy
  • Any ocular or periocular infection in the past twelve (12) weeks.
  • History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02387957


  Show 24 Study Locations
Sponsors and Collaborators
Ophthotech Corporation
  More Information

Responsible Party: Ophthotech Corporation
ClinicalTrials.gov Identifier: NCT02387957     History of Changes
Other Study ID Numbers: OPH1006
First Submitted: March 9, 2015
First Posted: March 13, 2015
Last Update Posted: April 5, 2017
Last Verified: April 2017

Keywords provided by Ophthotech Corporation:
Wet AMD
subfoveal choroidal neovascularization
Fovista®
Avastin®
Lucentis®
Eylea®

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Bevacizumab
Ranibizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Immunologic Factors